These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12365212)

  • 1. GLUT1 antibody staining in thin-layer specimens of benign and malignant body cavity effusions.
    Mensch LS; Weller L; Simmons-Arnold L; Gibson PC; Leiman G; Beatty B
    Acta Cytol; 2002; 46(5):813-8. PubMed ID: 12365212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
    Afify A; Zhou H; Howell L; Paulino AF
    Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
    Hafez NH; Tahoun NS
    J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved identification of malignant cells in serous effusions using a small, robust panel of antibodies on paraffin-embedded cell suspensions.
    Grefte JM; de Wilde PC; Salet-van de Pol MR; Tomassen M; Raaymakers-van Geloof WL; Bulten J
    Acta Cytol; 2008; 52(1):35-44. PubMed ID: 18323273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of CA 15-3 antibody in detecting metastatic adenocarcinoma.
    Huang Y; Zimmerman RL; Bibbo M
    Anal Quant Cytol Histol; 2004 Oct; 26(5):259-62. PubMed ID: 15560531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative study of the expression of CEA and a myelomonocytic antigen (CD15) in serous effusions using two monoclonal antibodies NEO 723 and Leu M1].
    Daste G; Berthier F; Mauduyt MA; Soleilhavoup JP
    Arch Anat Cytol Pathol; 1992; 40(4):183-9. PubMed ID: 1294046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of metabolic phenotypes in malignant pleural effusions: expression of GLUT1 and CAIX by immunocytochemistry.
    Liao ND; Shieh JM; Lee WY
    Cancer Cytopathol; 2011 Oct; 119(5):346-53. PubMed ID: 21442770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of a second generation CA 15-3 antibody to detect adenocarcinoma in body cavity effusions.
    Zimmerman RL; Fogt F; Goonewardene S
    Cancer; 2000 Aug; 90(4):230-4. PubMed ID: 10966563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
    Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
    Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
    Ko EC; Jhala NC; Shultz JJ; Chhieng DC
    Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLUT1 glucose transporter: a highly sensitive marker of malignancy in body cavity effusions.
    Burstein DE; Reder I; Weiser K; Tong T; Pritsker A; Haber RS
    Mod Pathol; 1998 Apr; 11(4):392-6. PubMed ID: 9578091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW; Papadimos DJ; Walsh MD
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P53-immunoreactive cells in benign and malignant effusions: diagnostic value using a panel of monoclonal antibodies and comparison with CEA-staining.
    Stoetzer OJ; Munker R; Darsow M; Wilmanns W
    Oncol Rep; 1999; 6(2):455-8. PubMed ID: 10023021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.
    Davidson B; Risberg B; Kristensen G; Kvalheim G; Emilsen E; Bjåmer A; Berner A
    Virchows Arch; 1999 Jul; 435(1):43-9. PubMed ID: 10431845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3.
    Martin SE; Moshiri S; Thor A; Vilasi V; Chu EW; Schlom J
    Am J Clin Pathol; 1986 Jul; 86(1):10-8. PubMed ID: 3524191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indian file pattern of adenocarcinoma cells in effusions.
    Hemachandran M; Dey P
    Acta Cytol; 2004; 48(3):385-6. PubMed ID: 15192955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of malignant cells in serous effusions using a panel of monoclonal antibodies Ber-EP4, MCA-b-12 and EMA.
    Stoop JA; Hendriks JG; Berends D
    Cytopathology; 1992; 3(5):297-302. PubMed ID: 1288655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions.
    Johnston WW; Szpak CA; Lottich SC; Thor A; Schlom J
    Cancer Res; 1985 Apr; 45(4):1894-900. PubMed ID: 3884146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moc-31, fibronectin and CEA in the differential diagnosis of malignant effusions: an immunocytochemical study.
    Athanassiadou P; Gonidi M; Liossi A; Petrakakou E; Nakopoulou L; Zerva C; Athanassiades P
    Pathol Oncol Res; 2000; 6(2):100-3. PubMed ID: 10936783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.